Lys K endolysin is synergistic with lysostaphin against MRSA
AssigneeThe United States of America as represented by the Secretary of Agriculture
InventorsDavid M. Donovan, Stephen C. Becker
Life of this patent
Estimating the term…
Abstract
Multi-drug resistant superbugs are a persistent problem in modern health care. LysK is a staphylococcal bacteriophage endolysin from the phage K. It is a peptidoglycan hydrolase enzyme that can lyse many staphylococcal strains and thus is a potent antimicrobial against S. aureus, including MRSA. Lysostaphin is a bacteriocin secreted by S. simulans to kill S. aureus, and has been shown to also be a potent antimicrobial for many antibiotic resistant strains of S. aureus. This study describes optimal reaction conditions for the recombinant His-tagged LysK protein, compares its MIC and antimicrobial activity to lysostaphin and demonstrates synergy when the two are used in combination against the MRSA USA300.
Claims8
An antimicrobial pathogen-specific composition comprising an isolated, recombinant LysK endolysin and an isolated, recombinant lysostaphin and a pharmaceutically acceptable carrier, wherein said composition is functional for degrading the peptidoglycan cell wall of untreated, live Staphylococcus aureus including methicillin-resistant Staphylococcus aureus.
A kit, comprising a composition for treatment of disease caused by the bacteria for which the LysK endolysin and lysostaphin are specific, wherein said kit comprises isolated, recombinant LysK endolysin and isolated, recombinant lysostaphin.
A composition useful for the treatment of diseases and infections caused by the bacteria for which the LysK endolysin and lysostaphin are effective against where the composition comprises LysK endolysin and lysostaphin each in amounts that act synergistically together to effectively treat said diseases and infections.
Dependencies are inferred from the claim text.